<?xml version="1.0" encoding="UTF-8"?>
<p>Erectile dysfunction (ED) as well as impotence is a multifactorial (psychogenic, neurogenic, vasculogenic, endocrine/metabolic, end organ disease and iatrogenic) health issue common in 20–30% of adult men worldwide (
 <xref rid="B114" ref-type="bibr">McMahon, 2019</xref>; 
 <xref rid="B169" ref-type="bibr">Taylor et al., 2019</xref>). It negatively impacts patient’s sexual satisfaction and psychological well-being, leading to a greater prevalence of anxiety and depression. Lifestyle changes in combination with oral phosphodiesterase type 5 inhibitors (PDE5Is: sildenafil, tadalafil, vardenafil and avanafil) are typically first-line treatments of most etiologies of ED (
 <xref rid="B69" ref-type="bibr">Hatzimouratidis et al., 2016</xref>; 
 <xref rid="B89" ref-type="bibr">Krzastek et al., 2019</xref>; 
 <xref rid="B118" ref-type="bibr">Moses et al., 2019</xref>). PDE5Is increase arterial blood flow into the penis (via relaxion of the 
 <italic>corpus cavernosum</italic> and deep penile artery smooth muscles) and reduce the venous outflow leading to the penile erection. Among PED5Is, only sildenafil is cost-effective as it is the only PDE5-I with a generic option. PED5Is are commonly associated with side effects (flushing, hypotension, headache, dyspepsia, back pain, myalgia, dizziness, blurred vision and rhinitis) and a lot of contraindications that contribute to significant treatment dropout rates (
 <xref rid="B184" ref-type="bibr">Yuan et al., 2013</xref>; 
 <xref rid="B183" ref-type="bibr">Yafi et al., 2018</xref>). Moreover, up to 40% of ED patients fail to respond sufficiently to the maximum dose of PDE5Is (
 <xref rid="B145" ref-type="bibr">Porst et al., 2013</xref>).
</p>
